REGistry of Long-term AnTithrombotic TherApy-2

Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Atrial Fibrillation

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04347187

Acronym

REGATTA-2

Enrollment

2000

Registered

2020-04-15

Start date

2015-01-15

Completion date

2026-12-31

Last updated

2026-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Keywords

atrial fibrillation, coronary artery disease

Brief summary

To assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with atrial fibrillation

Detailed description

The register is a Russian prospective single-center observational study of patients who have indications for long-term antithrombotic therapy in connection with atrial fibrillation

Interventions

DRUGAnticoagulants

oral anticoagulants, dual or triple antithrombotic theraphy

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Documented atrial fibrillation with CHA2DS2VASC \> 1

Exclusion criteria

* Subjects who are unwilling or unable to provide informed consent. ACS within 12 months before inclusion Severe CHF (NYHA IV) Stroke within 6 months before inclusion Severe liver or muscle disease Severe kidney disease / renal failure with creatinine \> 3 mg/dl Conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention

Design outcomes

Primary

Measure	Time frame	Description
composite of major cardiovascular events	unclusion up to 5 years	stroke, myocardial infarction, stent thrombosis \[definite or probable\], or urgent revascularization, cqrdiac death
composite of any bleeding events	unclusion up to 5 years	major, clinically relevant nonmajor, minor (BARC, ISTH,GARFIELD AF)

Secondary

Measure	Time frame	Description
Mutations in following genes	inclusion	CYP2C9\*, VKORC1

Countries

Russia

Contacts

CONTACTEkaterina Kropacheva, PhD

katekrab@list.ru+79166760695

PRINCIPAL_INVESTIGATORElizaveta Panchenko, PhD

National Medical Research Center for Cardiology, Ministry of Health of Russian Federation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 2, 2026